Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.

Area of Science:

• Neuroimmunology
• Biochemistry
• Biomarker Discovery

Background:

• Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) regulate extracellular matrix remodeling.
• Imbalances in MMP/TIMP activity are implicated in multiple sclerosis (MS) pathogenesis.
• Specific MMPs and TIMPs may correlate with different MS disease types and activity levels.

Purpose of the Study:

• To characterize serum and cerebrospinal fluid (CSF) matrix metalloproteinase-2 (MMP-2) and MMP-9 activities relative to their inhibitors, TIMP-2 and TIMP-1.
• To investigate these MMP/TIMP ratios as potential biomarkers for different multiple sclerosis (MS) subtypes and disease activity.

Main Methods:

• Quantification of MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in serum and CSF.
• Calculation of MMP/TIMP ratios for different patient groups: short disease duration (SDD) relapsing-remitting (RR) MS, secondary progressive (SP) MS, primary progressive (PP) MS, and healthy controls (HC).
• Correlation analysis of MMP/TIMP ratios with clinical and MRI-defined disease activity.

Main Results:

• Serum MMP-2/TIMP-2 ratios were elevated in SP and PP MS compared to SDD RR MS, but similar to HC.
• Serum MMP-9/TIMP-1 ratios were higher in SDD RR MS than PP MS and associated with active disease (clinical and MRI).
• CSF MMP/TIMP ratios did not differ significantly between MS subtypes, suggesting systemic rather than central nervous system-specific changes.

Conclusions:

• An increased serum MMP-2/TIMP-2 ratio may indicate chronic progression in MS.
• Elevated serum MMP-9/TIMP-1 activity is characteristic of active and early relapsing forms of MS.
• Serum MMP/TIMP ratios show potential as systemic biomarkers differentiating MS disease phenotypes and activity.